FSCN2

FSCN2 is short for "fascin actin-bundling protein 2, retinal," and it belongs to a family of proteins that bundle actin, one of the building materials that gives cells their shape. This particular fascin is made almost exclusively in the retina, and researchers believe it helps build and maintain the stacked discs inside photoreceptor (definition: A light-sensing cell in the retina. Rods (used for night and peripheral vision) and cones (used for color and detail) are the two types.) cells that capture light. The gene sits on chromosome 17 and is also known by the older names RFSN and RP30. Because a healthy retina depends on well-maintained photoreceptor structure, a gene involved in that structure was a reasonable candidate to investigate in inherited retinal disease.

In the earliest reports, a specific FSCN2 change (called 208delG) was described in Japanese families whose vision loss followed either a retinitis pigmentosa pattern or a macular degeneration pattern, sometimes within the same family. Retinitis pigmentosa typically affects side and night vision first, while macular degeneration affects the sharp central vision used for reading. More recent single-patient case reports have instead linked rare FSCN2 variants to a cone-rod dystrophy pattern, in which central and color vision are affected, often with a distinctive area of change near the center of the retina. Because these reports describe very few people and the gene's overall role is contested, they should be seen as possible rather than confirmed associations.

It is well established that FSCN2 is switched on specifically in the retina and produces an actin-bundling protein thought to support photoreceptor (definition: A light-sensing cell in the retina. Rods (used for night and peripheral vision) and cones (used for color and detail) are the two types.) disc formation. In mice, removing or disabling the Fscn2 gene causes the photoreceptors to degenerate over time and weakens the retina's electrical responses to light. This animal evidence shows the gene matters for a healthy retina, but findings in mice do not prove that FSCN2 variants cause disease in people. The original human association was reported in Japanese families, where the 208delG change appeared in a small percentage of those with dominant retinitis pigmentosa.

The central uncertainty is whether FSCN2 truly causes human retinal disease at all. A study of Chinese individuals found the same 208delG change in healthy people and in unaffected family members, and it did not track with disease within families, directly contradicting the original report. A Spanish study found many FSCN2 sequence variations but none that clearly matched disease within families, and a large survey of 200 dominant retinitis pigmentosa families in the United States found no disease-causing FSCN2 mutations. A copy-number analysis further suggested that the widely reported 208delG (c.72delG) variant is not the primary cause of retinitis pigmentosa. In several gene-panel studies, FSCN2 changes have been reported only as variants of uncertain significance, meaning their effect on health is unknown. Laboratory work has also placed FSCN2 downstream of other retinal genes such as PRPF31, suggesting its activity can be affected indirectly, but this does not establish FSCN2 itself as a disease cause.

As of the date of this review, no treatment targeting FSCN2 has been approved, and the supplied evidence does not identify any gene-specific therapy. Most FSCN2 research to date has focused on understanding what the protein does, using mice and cultured cells rather than testing treatments. Some laboratory studies describe FSCN2 as a potential therapeutic target within the biology of another retinitis pigmentosa gene, PRPF31, but this remains early experimental work, not an available therapy. Notably, mice lacking Fscn2 develop both progressive hearing loss and retinal changes, which is a laboratory observation and has not been established as a human syndrome tied to this gene.

• Mouse studies of Fscn2 loss

  Animal (preclinical) research

  What was found:

  The mice showed progressive photoreceptor degeneration and weaker retinal electrical responses with age.

  Why it matters:

  It shows the gene is important for a healthy retina and helps explain why it was a plausible candidate.

  Limitation: Findings in mice do not establish that FSCN2 variants cause disease in humans.

• The original report linking FSCN2 to dominant retinitis pigmentosa

  Human observational case series

  What was found:

  The change was present in about 3.3% of the dominant retinitis pigmentosa patients studied, with typical retinitis pigmentosa features.

  Why it matters:

  This is the study that first placed FSCN2 on the list of possible retinitis pigmentosa genes.

  Limitation: It was limited to one population and did not, by itself, prove the variant causes disease — later studies challenged this conclusion.

• Evidence against the FSCN2 disease link in Chinese individuals

  Human observational study

  What was found:

  The change appeared in healthy control subjects and unaffected relatives and did not track with disease within families.

  Why it matters:

  It directly contradicts the original claim and is a key reason FSCN2's role is now considered disputed.

  Limitation: It focused on one specific variant in one population, though its findings echo other negative studies.

• Large survey of dominant retinitis pigmentosa families

  Human observational study

  What was found:

  Disease-causing mutations were identified in several genes, but none were found in FSCN2.

  Why it matters:

  It suggests FSCN2 contributes little or nothing to dominant retinitis pigmentosa in this large cohort.

  Limitation: A negative result in one large mostly European-origin cohort does not completely exclude rare contributions elsewhere.

• Recent case report of a cone-rod dystrophy pattern

  Single human case report

  What was found:

  He had a cone-rod dystrophy pattern with a distinctive central retinal abnormality resembling earlier FSCN2 reports.

  Why it matters:

  It keeps open the possibility that certain rare FSCN2 variants contribute to central retinal disease.

  Limitation: One patient cannot establish that the gene causes disease, and the association overall remains disputed.

This gene does not have distinct, well-established caregiver considerations beyond the general guidance shown on every gene page, though the disputed genetic cause is worth keeping in mind when relatives consider testing.

• How was my FSCN2 variant classified — pathogenic, likely pathogenic, or a variant of uncertain significance?
• Given that FSCN2's role in retinal disease is disputed, could another gene in my results better explain my diagnosis?
• Does my retinal exam and imaging pattern fit any of the presentations reported with FSCN2?
• Would additional or updated genetic testing help clarify the cause of my condition?
• Should other family members consider evaluation, and what would that involve?
• How will you monitor my vision over time regardless of the genetic uncertainty?

Because FSCN2's link to retinal disease is disputed, it is especially worthwhile to review with a genetic counselor or retinal specialist how a specific FSCN2 finding was classified and whether another gene might better explain the diagnosis. A thorough evaluation often looks at the whole genetic testing report rather than a single gene, since some people carry additional variants that are more clearly relevant. RP Hope's genetic testing resource explains what testing involves and what questions to bring to that conversation.